Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

2.64USD
21 Sep 2017
Change (% chg)

$-0.01 (-0.38%)
Prev Close
$2.65
Open
$2.66
Day's High
$2.72
Day's Low
$2.61
Volume
4,071,308
Avg. Vol
4,746,706
52-wk High
$7.15
52-wk Low
$2.57

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals secures $300 mln debt financing
Tuesday, 5 Sep 2017 08:30am EDT 

Sept 5 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals secures $300 million debt financing.Synergy Pharmaceuticals- financing structure provides access to capital for support of commercialization of TRULANCE, funds current plans through 2019​.  Full Article

Synergy Pharma Q2 sales $2.3 million
Wednesday, 9 Aug 2017 04:30pm EDT 

Aug 9 (Reuters) - Synergy Pharmaceuticals Inc ::Synergy Pharmaceuticals reports second quarter 2017 financial results and business update.Q2 sales $2.3 million versus I/B/E/S view $2 million.Synergy Pharmaceuticals Inc - ‍FDA has accepted for review SNDA for Trulance for treatment of adults with IBS-C​.Synergy Pharmaceuticals Inc - ‍PDUFA date for Trulance is January 24, 2018​.Synergy Pharmaceuticals Inc qtrly net loss per common share $0.23.Q2 earnings per share view $-0.25, revenue view $2.0 million -- Thomson Reuters I/B/E/S.  Full Article

Synergy Pharmaceuticals says acceptance of SNDA for TRULANCE for treatment of adults with irritable bowel syndrome with constipation
Wednesday, 7 Jun 2017 09:00am EDT 

June 7 (Reuters) - Synergy Pharmaceuticals Inc ::Synergy Pharmaceuticals Inc says acceptance of SNDA for Trulance for treatment of adults with irritable bowel syndrome with constipation.Synergy Pharmaceuticals Inc says prescription drug user fee act (PDUFA) date is January 24, 2018.  Full Article

Synergy Pharmaceuticals reports Q1 sales $100,000
Wednesday, 10 May 2017 04:54pm EDT 

May 10 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports first quarter 2017 financial results and business update.Q1 sales $100,000.Q1 revenue view $25,000 -- Thomson Reuters I/B/E/S.Qtrly net loss per common share, basic and diluted $0.30.Q1 earnings per share view $-0.23, revenue view $25000.00 -- Thomson Reuters I/B/E/S.  Full Article

Synergy Pharmaceuticals appoints Gary Gemignani as chief financial officer
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Synergy Pharmaceuticals Inc -:Synergy Pharmaceuticals appoints Gary G. Gemignani as chief financial officer.Gemignani replaces senior vice president, finance, Bernard Denoyer.Bernard Denoyer, who will assist in transition process until his retirement on July 1, 2017.  Full Article

Synergy Pharmaceuticals announces issuance of three new patents expected to extend Trulance patent protection until 2032
Wednesday, 12 Apr 2017 08:00am EDT 

Synergy Pharmaceuticals Inc : Announces issuance of three new patents expected to extend Trulance (Plecanatide) patent protection until 2032 .United States Patent and Trademark Office (USPTO) has issued three new patents covering Trulance (Plecanatide).  Full Article

Synergy Pharmaceuticals reports qtrly net loss per common share $0.31
Wednesday, 1 Mar 2017 04:42pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update . Qtrly net loss per common share $0.31 . Q4 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S .Synergy pharmaceuticals inc- remain on-track to file a supplemental new drug application this month for trulance.  Full Article

Synergy Pharmaceuticals announces proposed public offering of common stock
Tuesday, 31 Jan 2017 04:01pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces proposed public offering of common stock . Synergy Pharmaceuticals Inc- intends to use net proceeds from offering to fund its commercialization activities related to trulance . Synergy Pharmaceuticals Inc says to sell $125 million of its common stock .Synergy Pharmaceuticals Inc- also intends to use net proceeds from offering to further clinical development of plecanatide.  Full Article

Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation
Thursday, 19 Jan 2017 06:35pm EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation .Synergy Pharmaceuticals - Plans to file new drug application supplement with clinical data later this quarter for Trulance.  Full Article

FDA approves Trulance for chronic idiopathic constipation
Thursday, 19 Jan 2017 04:05pm EST 

Synergy Pharmaceuticals Inc : FDA approves Trulance for chronic idiopathic constipation .FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc.  Full Article